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 Chapter 5 
 
 Total synthesis of DAT2 
The availability of bio-markers for lipidomic platforms in 
Mycobacterium tuberculosis is crucial to the recognition of 
species or strains. To provide one of these markers, this 
chapter describes the synthesis of DAT2, a di-acyl trehalose. 
In addition to its use as a bio-marker, DAT2 is involved in the 
immune response in humans, making it an interesting 
compound for further investigation. For the synthesis of DAT2, 
mycolipanolic acid was prepared in a protected form and 
acylated to the trehalose core. Although a final fourfold 
deprotection was envisioned, this proved to be more 












 Mycobacteria are formally Gram-positive bacteria, responsible for a wide range of 
serious diseases like leprosy, buruli ulcer, tuberculosis and others. All mycobacteria have a 
lipid-rich cell wall, which is responsible for the difficult treatment of tuberculosis infections.[1] 
The profiling of mycobacteria has gained considerable interest over the past years, as 
identification of species and strains is invaluable for the treatment of infected individuals. 
Because cell division of M. tuberculosis is very slow (22–24 h), analysis of strains is time-
consuming. With the development of comparative lipidomic platforms, species- and strain-
specific (glyco)lipids can be identified, more providing more rapid access to the sought-
after information. To prepare these profiles, the availability of bio-markers which can 
identify the pathogenicity of mycobacteria, is important.[2] In addition to their potential use 
as bio-markers, 2,3-di-acyl trehaloses have been found to inhibit part of the immune 
response after infection with M. tuberculosis.[3] One of the lipids that can be used in the 
analysis of M. tuberculosis and is found only in virulent strains, is a 2,3-di-acyl trehalose 
termed DAT2 (5.1, Figure 5.1).[4]  
 
Figure 5.1 DAT2 
 2,3-di-O-acyl α,α-trehalose esters bearing long-chain fatty acids have been found in 
isolates from multiple mycobacteria. For example, Mycobacterium fortuitum contains a 
glycolipid with (E)-2-methyloctadec-2-enoyl as the major component acylated at the 3-
position.[5] 2,3-di-acyl trehaloses from Mycobacterium tuberculosis have been found to 
carry, besides simple fatty acids at the 2-position, a range of more complex fatty acids at 
the 3-position.[4a] Two of these are mycolipenic acid (5.2), found as part of penta-acyl 
trehaloses and di-acyl trehaloses, and mycolipanolic acid, found as part of DAT2.[4c] Both 
compounds are obviously closely related, and their biosyntheses have the same precursor, 
however the synthesis of mycolipenic acid involves an additional dehydration step.  
 




Figure 5.2 Mycolipenic acid 
 5.1 consists of a trehalose core, which is acylated at the 2- and 3-positions with palmitic 
and mycolipanolic acid, respectively.[4b] Like phthioceranic and hydroxyphthioceranic acid, 
but unlike mycocerosic acid, the 1,3-methyl ramifications in mycolipanolic acid are all-syn 
(S)-configured. It is assumed that the biosynthesis of mycolipanolic acid is carried out by 
the polyketide synthase PKS3/4.[6]  
 Although strategies towards the chemical synthesis of 2,3-di-acyl trehaloses have been 
reported (vide infra), DAT2 has never been prepared. Our aim was to prepare DAT2 by 
chemical synthesis giving access to the pure material that can be used in lipodomics and 
to study its immunological function. 
5.2 Reported syntheses of mycolipanolic acid 
 To date, two syntheses of mycolipanolic acid have been reported. In 1996, Minnikin et 
al. reported the first synthesis, although in a racemic fashion (Scheme 5.1).[7] They 
commenced their synthesis with the oxidation of racemic 3,5-dimethylcyclohexan-1-ol, 
followed by a Baeyer-Villiger oxidation to give the lactone. Ring-opening under basic  
 





conditions gave the carboxylic acid, which was transformed into the methyl ester using 
iodomethane. The methyl ester was reduced with LiAlH4, after protection of the primary 
alcohol as its trityl ether. Oxidation of the resulting primary alcohol, followed by Wittig 
olefination, introduced the long aliphatic chain. Removal of the trityl protecting group with 
TFA and hydrogenation of the double bond afforded the primary alcohol. Oxidation to the 
aldehyde, followed by aldol reaction with methyl propionate gave rise to the corresponding 
β-hydroxy ester. Protection of the secondary hydroxyl group as its TBS ether and basic 
hydrolysis of the methyl ester, afforded mycolipanolic acid in a protected form, equipped to 
be esterified to the carbohydrate moiety. 
 In 2010, the first asymmetric synthesis of mycolipanolic acid was reported 
(Scheme 5.2). Using Cu-catalyzed conjugate addition of methylmagnesium bromide to α,β-
unsaturated thioesters, as in the synthesis of phthioceranic and hydroxyphthioceranic acid 
(Chapter 2), two methyl ramifications were introduced with high stereoselectivity.[8] 
Reduction of the thioester, followed by tosylation of the resulting primary alcohol allowed 
the introduction of the long aliphatic chain. Cleavage of the silyl ether, followed by a Ley 
oxidation set the stage for an Evans aldol reaction, affording the syn β-hydroxy acyl 
oxazolidinone with excellent diastereoselectivity, but a moderate 45% yield. 
 
Scheme 5.2 Stereoselective synthesis of mycolipanolic acid 
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Finally, removal of the chiral auxiliary with, in situ generated, aqueous LiOOH afforded 
mycolipanolic acid in 16% yield. Although the yield of this last step is disappointing, this 
was reported to be due to chromatography problems and could be circumvented by 
altering the eluent. The overall yield over eleven steps is 2%.  
5.3 Reported syntheses of DAT2 analogues 
 Because of the aforementioned interesting properties of 2,3-diacyl trehaloses, attempts 
have been made to chemically prepare analogues of them. Although enantiopure 
mycolipenic and mycolipanolic acid were not available at the time, these investigations 
opened up a route towards the actual antigens from M. tuberculosis.  
 





In 1993, the first synthesis of a DAT2 analogue was reported by Baer and Wu.[9] 
Commencing from the known 4,6-4',6'-dibenzylidene trehalose (Scheme 5.3), a 
regioselective stannylation allowed the introduction of a palmitoyl moiety on the 2-position 
inducing a desymmetrization. Protection of the 2'- and 3'-OH as a bis(diisopropylsilyl) ether 
left 3-OH available for acylation. After acylation with palmitoyl chloride, the 
bis(diisopropylsilyl) ether was cleaved, followed by the final removal of the benzylidene 
acetals using iodine in methanol to afford the desired product. Overall, the yield of this 
approach is good and the individual steps are straightforward, rendering it a good tactic for 
the synthesis of DAT2. 
 
Scheme 5.4 Preparation of a DAT2 analogue as reported by Minnikin 
 In the same year, Minnikin et al. also reported the synthesis of 2,3-diacyl trehaloses,[10] 
based upon studies on the preparation of 4,6-2',3'-4',6'-tricyclohexylidene α,α-trehalose 
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reported earlier (Scheme 5.4).[11] Whereas many acetal forming reagents were unable to 
protect α,α-trehalose at six positions simultaneously in satisfactory yield, the 
cyclohexylidene group proved to be crucial for the desired hexa-protection in the first 
step.Regioselective acylation with a DCC-mediated esterification, followed by a second 
DCC-mediated esterification delivered the tri-cyclohexyl di-acylated intermediate in good 
yield. The strength of the approach by Minnikin et al. lies in the small number of steps, as 
deprotection of the cyclohexylidenes under acidic conditions directly affords the desired 
2,3-diacyl trehalose. Using these results, a 2,3-diacyl trehalose isolated from M. fortuitum 
was prepared.[12] The yield of the final deprotection is disappointing, which was attributed 
to incomplete hydrolysis. However, no comment on any identified side-products is given. 
Moreover, the second esterification of 3-OH requires an excess of the fatty acid in both 
reported syntheses. For the esterification of precious chiral fatty acids, needed to complete 
the synthesis of DAT2, an alternative should be investigated.  
5.4 Strategy 
 As the reported route to mycolipanolic acid is straightforward and delivers the product 
as a single enantiomer,[8] we decided to use this synthesis as a guideline and try to 
improve the yields where possible. However, to acylate mycolipanolic acid to the 
carbohydrate core we realized that a protecting group on the β-hydroxy functionality was 
required.  
 





 To install the palmitic and mycolipanolic acid regioselectively onto the carbohydrate, 
multiple considerations had to be made (Scheme 5.5). The choice of protecting group(s) on 
the trehalose seemed crucial for the success of the synthesis. We reasoned that the 
strategy reported by Minnikin, installing cyclohexylidene moieties on three dihydroxy 
functions, would be the most direct route to first install the palmitoyl and subsequently the 
mycolipanoyl moiety.[10] Most ideally, the removal of all protecting groups should be 
performed in a single step, limiting the number of steps and the purification of highly polar 
intermediates.  
5.5 Carbohydrate protecting-group strategy 
The moderate yield of the initial threefold protection of trehalose is not considered a big 
disadvantage; it is the first step in the synthesis and the materials are readily available. The 
low yield in the final deprotection, however, is more problematic, all the more so, because 
the (protected) β-hydroxyl moiety in the mycolipanolic ester is prone to elimination under 
acidic conditions. Therefore, protection of the hydroxyl functions on the 4,6-,4',6' and 2,3-
positions as their benzylidene acetals was considered. In the synthesis of Ac2SGL 
(chapter 3) and sulfolipid-1 (chapter 4), the deprotection of these acetals proved higher-
yielding than the reported cyclohexylidene deprotection. In addition, the essentially neutral 
conditions necessary for the removal of the benzylidene acetals would be tolerated by the 
β-hydroxyl moiety in the mycolipanolic residue. 
Scheme 5.6 Attempted tri-protection of trehalose 
 Despite literature precedent, the envisioned route already failed in the first step. The tri-
protection, using conditions similar to those reported by Minnikin et al.,[10] failed to produce 
any of the desired product (Scheme 5.6). The main isolated product was the 4,6-4',6' 
dibenzylidene acetal, next to some unidentified products.  
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 A second approach made use of the so-obtained 4,6-4',6' di-acetal 3.2 (see also 
Chapter 3). Conversion was, however, minimal and no desired product was obtained. 
Scheme 5.7 Formation of the tri-protected trehalose 
 Obliged, we turned our attention to the originally described tri-protection procedure by  
Minnikin. Using slightly modified conditions, tri-protected 5.4 was obtained in 34% yield (lit. 
42%), along with ~40% of the 4,6-4',6' di-protected compound (Scheme 5.7). 
5.6 Synthesis of mycolipanolic acid 
 The synthesis of mycolipanolic acid started according to the reported procedure.[8] After 
introduction of two methyl ramifications, thioester 5.5 was reduced to primary alcohol 5.6 
using DIBALH (Scheme 5.8). As direct reduction to the alcohol is hampered by the 
robustness of the tetrahedral intermediate, due to considerable overlap of sulfur 3p orbitals 
with the empty 3p orbital of aluminium, a two-step protocol with an intermediate work-up 
was necessary. Transformation of the alcohol into tosylate 5.7 was achieved by an 
improved procedure, affording 5.7 in 90% yield. The introduction of the long alkyl chain and  
 





subsequent removal of the silyl ether yielded primary alcohol 5.9, although in slightly lower 
yields than anticipated. 
 In order to investigate the subsequent reactions towards a protected form of 
mycolipanolic acid, we decided to prepare model substrate 5.11 (Scheme 5.9). Starting 
from butyraldehyde, an Evans aldol reaction was performed delivering 5.11 in good yield 
and excellent diastereoselectivity. It must be noted that the use of a fresh batch of n-
Bu2BOTf was required, as an older batch did not afford any product. The preparation of 
5.11 also allowed to support our hypothesis that acylation of mycolipanolic acid at the 3-
position of trehalose was possible, and selective deprotection without elimination of the β-
hydroxy group would be effective. As tricyclohexylidene 5.4 was selected as the most 
direct route to DAT2, we chose to protect the secondary alcohol of 5.11 as its TBS-ether 
given that this would allow concurrent deprotection in the final step. TBS-protection was 
readily achieved, affording 5.12 in good yield. The chiral auxiliary was subsequently 
removed with aqueous LiOOH to furnish carboxylic acid 5.13.  
 
Scheme 5.9 Preparation of carboxylic acid 5.13 
 For the preparation of TBS-protected mycolipanolic acid, the same approach was used 
(Scheme 5.10). In order to oxidize 5.9 to aldehyde 5.14, the attention was turned to 
hypervalent iodine chemistry, as previous attempts with the Ley oxidation afforded low 
yields in the subsequent Evans aldol reaction. The reason for this was not clear but 
rigorous purification of the intermediate aldehyde was not possible due to its lability. Using 
Dess-Martin periodinane, the syn β-hydroxy acyl oxazolidinone 5.15 was obtained in 70% 
yield after Evans aldol reaction. The diastereoselectivity was shown to be at least identical 
to that reported, as no diastereomer was detected by 1H- and 13C-NMR spectroscopy. 
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Finally, protection of the secondary alcohol as its TBS ether (5.16) and removal of the 
chiral auxiliary yielded 5.17. 
 
Scheme 5.10 Synthesis of TBS-protected mycolipanolic acid  
5.7 Completion of the synthesis of DAT2 
 The final steps in the synthesis of DAT2 were initially investigated with the previously 
prepared model substrate 5.13 (Scheme 5.11). To acylate 5.13 at the 3-position of 5.4, first 
a palmitoyl group had to be introduced at the 2-position. Using a DCC-mediated coupling, 
palmitic acid was regioselectively introduced at 2-OH. The free 3-OH was then acylated 
using a previously employed Yamaguchi esterification with 5.13 in an excellent 96% yield. 
Full deprotection was indeed achieved under acidic conditions, removing the three 
cyclohexylidene and the TBS group. However, the 20% yield was not very satisfying. 
Although all starting material was consumed, TLC analysis revealed multiple more apolar 
products of which two were recognized as palmitic acid and 5.13, indicating partial 
hydrolysis of the ester groups. Although the final deprotection is not ideal and leaves room 







Scheme 5.11 Preparation of a DAT2 analogue 
 For the actual preparation of DAT2, the same procedure as applied to the model 
substrate was followed (Scheme 5.12). Intermediate 5.18 was acylated with the 
Yamaguchi protocol with carboxylic acid 5.17 to afford 5.21 in 65% yield. Although the yield 
was somewhat lower than for model substrate 5.19, the larger steric hindrance of the 
intermediate mixed anhydride could account for a considerably slower reaction. Whether or 
not an increased reaction time leads to a higher yield still has to be determined. To 
increase the yield of the final deprotection, an attempt with less harsh deprotection 
conditions was made. The use of a 1:10 THF/AcOH (80% in water) mixture showed 
conversion of the starting material after stirring at rt for three days, but no product 
formation. For this reason, the attention was turned to the use of THF/HCl (10% in water). 
After stirring for two days, 1H-NMR spectroscopy indicated the formation of one main 
product. Although several less polar products were formed, one main product could be 
isolated in 28% yield. 1H-NMR spectroscopy indicated that the majority of the protecting 
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groups was cleaved, however, the TBS-ether was untouched. Submitting the recovered 
substrate to aqueous HF in acetonitrile, led, surprisingly, not to the formation of 5.1, but 
resulted in partial degradation.[13] As we were unsure whether 5.22 would be soluble in an 
acetonitrile/water mixture, 5.22 was redissolved in EtOH/DCM (1:1) and few drops of 
aqueous HF were added. After 5 h, no conversion was observed. Due to time constraints, 
additional attempts to complete the synthesis of 5.1 could not be executed.  
 
Scheme 5.12 Final steps toward DAT2 
5.8 Conclusions and outlook 
 Until now, we have not been able to complete the synthesis of DAT2. Toward its 
synthesis, the preparation of mycolipanolic acid as described by Minnaard et al. was 
followed. Protection of mycolipanolic allowed the regioselective acylation to a protected 
trehalose core which, after deprotection, was envisioned to give direct access to DAT2. 
Although all cyclohexylidene moieties were cleaved, the TBS group on 5.21/5.22 proved 





increased steric hindrance is most probably the cause for the reduced reactivity. To 
eventually obtain DAT2, and to optimize the synthesis, the final low-yielding deprotection of 
the cyclohexylidenes has to be studied in more detail. Also the cleavage of the TBS-
protecting group deserves additional attention. A more easily acid-cleaved protecting 
group, like TMS or TES, are suggested as alternatives. Further studies to complete the 
synthesis of 5.1 are currently under investigation. 
5.9 Experimental section 
For general experimental information: see Chapter 2. 
(3R,5S)-S-ethyl 6-((tert-butyldiphenylsilyl)oxy)-3,5-dimethylhexanethioate (5.5): Compound 
5.5 was prepared according to the reported procedure. All 
analytical data were in accordance to those reported.[8] 
(3R,5S)-6-((tert-butyldiphenylsilyl)oxy)-3,5-dimethylhexan-1-ol (5.6): Compound 5.6 was  
prepared according to the reported procedure in 87% yield over 
two steps. All analytical data were in accordance to those 
reported.[8] 
(3R,5S)-6-((tert-butyldiphenylsilyl)oxy)-3,5-dimethylhexyl 4-methylbenzenesulfonate (5.7):  
Compound 5.7 was prepared using a slightly adapted 
procedure. The alcohol was dissolved in CHCl3 (1.9 mL, final 
substrate concentration = 1 M) and cooled to 0 ºC using an ice-bath. Pyridine (2 eq) was 
added, followed by the addition of p-toluenesulfonyl chloride (1.5 eq) in small portions. 
After 4 h, TLC indicated complete consumption of the starting material and the reaction 
was diluted with Et2O (5 mL) and water (5 mL). The organic layer was successively 
washed with HCl (2 M), aq. NaHCO3 (5%) and water, and dried over MgSO4. Volatiles were 
evaporated and the crude mixture was purified using column chromatography 
(pentane/Et2O 10:1) to afford 5.7 as a colorless oil (90% yield). All analytical data were in 
accordance to those reported.[8] 
tert-butyl(((2S,4S)-2,4-dimethyldocosyl)oxy)diphenylsilane (5.8): Compound 5.8 was  
prepared according to the reported procedure in 75% yield. 
All analytical data were in accordance to those reported.[8] 
(2S,4S)-2,4-dimethyldocosan-1-ol (5.9): Compound 5.9 was prepared according to the  
reported procedure in 62% yield. All analytical data were in 
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accordance to those reported.[8] 
(S)-4-benzyl-3-((2S,3R)-3-hydroxy-2-methylhexanoyl)oxazolidin-2-one (5.11): To 
oxazolidinone 5.10[8] (100 mg, 0.51 mmol) in DCM (1.4 mL) at 0 ºC 
was slowly added n-Bu2BOTf (1.15 eq, 493 μL, 1 M solution in DCM, 
fresh bottle) over 5 min, followed by addition of Et3N (1.3 eq, 78 μL). 
The reaction mixture was cooled to –78ºC and butyraldehyde (40 μL, 0.45 mmol) was 
slowly added. After stirring for 20 min at –78 ºC, the reaction was allowed to gradually 
warm to 0 ºC and stirred at this temperature for an additional hour. The reaction was 
subsequently quenched with KH2PO4 buffer (1 mL, 0.1 M, pH 7) and MeOH (2 mL). Then, 
MeOH/H2O2 (2 mL, 2:1, 50%) mixture was added and the resulting solution was stirred 
vigorously for 1 h. The mixture was diluted with H2O (3 mL) and extracted with Et2O (3 x 
10 mL). The combined organic layers were successively washed with an aq. saturated 
solution of NaHCO3 and brine. The organic phase was dried over MgSO4, filtered and 
concentrated. The crude was purified using column chromatography (15% EtOAc in 
pentane) to afford the 5.11 as a white solid (98 mg, 75%). Analytical data were in 
accordance to those reported.[8] 
1H NMR (400 MHz, CDCl3) δ 7.35 – 7.16 (m, 5H), 4.72 – 4.65 (m, 1H), 4.24 – 4.13 (m, 2H), 
3.97 – 3.91 (m, 1H), 3.75 (qd, J = 7.0, 2.9, 1H), 3.23 (dd, J = 13.4, 3.3, 1H), 2.94 (bs, 1H), 
2.78 (dd, J = 13.4, 9.4, 1H), 1.57 – 1.44 (m, 2H), 1.43 – 1.31 (m, 2H), 1.24 (d, J = 7.1, 3H), 
0.92 (t, J = 7.1, 3H); 13C NMR (101 MHz, CDCl3) δ 177.33, 152.93, 134.94, 129.30, 
128.81, 127.27, 71.10, 66.04, 54.98, 42.06, 37.62, 35.91, 19.08, 13.88, 10.36. 
(S)-4-benzyl-3-((2S,3R)-3-((tert-butyldimethylsilyl)oxy)-2-methylhexanoyl)oxazolidin-2-one  
(5.12): To a solution of 5.11 (100 mg, 0.33 mmol) in DCM (1.0 mL, 
substrate concentration = 0.33 M) at 0 ºC was added 2,6-lutidine 
(1.4 eq, 53 μL), followed by TBSOTf (1.1 eq, 83 μL). The reaction was 
stirred at this temperature for 1 h and an additional 3 h at rt prior to quenching with KH2PO4 
buffer (1 mL, 0.1 M, pH 7). The aqueous layer was extracted with DCM (3 x 5 mL) and the 
combined organic layers were dried over MgSO4, filtered and evaporated. 5.12 (110 mg, 
80%) was isolated after column chromatography (pentane/EtOAc 20:1) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.37 – 7.20 (m, 5H), 4.65 – 4.58 (m, 1H), 4.22 – 4.10 (m, 2H), 
4.01 (dd, J = 10.8, 5.7, 1H), 3.93 – 3.79 (m, 1H), 3.30 (dd, J = 13.3, 3.0, 1H), 2.78 (dd, J = 
13.3, 9.7, 1H), 1.59 – 1.46 (m, 2H), 1.44 – 1.25 (m, 2H), 1.21 (d, J = 6.9, 3H), 0.94 – 0.86 





129.42, 128.89, 127.27, 72.68, 65.94, 55.78, 42.79, 37.83, 37.56, 25.79, 18.32, 18.01, 
14.36, 11.37, -4.18, -4.88; HRMS-(ESI+) for C46H74N2O8Si2Na [2M + Na]+ calculated 
861.4881 Da, found 861.4887 Da. 
(2S,3R)-3-((tert-butyldimethylsilyl)oxy)-2-methylhexanoic acid (5.13): To a solution of 5.12  
(90 mg, 0.21 mmol) in THF/H2O (2.5 mL, 4:1) was added H2O2 (4 eq, 
53 μL, 50%) and LiOH (1.5 eq, 13.5 mg) at 0 ºC. The mixture was 
allowed to slowly warm to rt and stirred for 18 h. The reaction was 
quenched by the addition of aq. saturated NaHSO3 (2 mL) and acidified afterwards with aq. 
citric acid (20 w/w%) to pH 3–4. The mixture was extracted with EtOAc (3 x 5 mL) and the 
combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. The 
residue was purified using column chromatography (pentane/EtOAc/AcOH 8:1:0.05) to 
afford acid 5.13 (35 mg, 63%) as a white solid. 
1H NMR (400 MHz, CDCl3) δ 11.06 (bs, 1H), 4.00 (m, 1H), 2.65 – 2.47 (m, 1H), 1.50 – 1.43 
(m, 2H), 1.33 – 1.22 (m, 2H), 1.13 (d, J = 7.0, 3H), 0.94 – 0.85 (m, 12H), 0.08 (s, 3H), 0.06 
(s, 3H); 13C NMR (101 MHz, CDCl3) δ 179.47, 73.40, 44.38, 36.42, 25.75, 18.61, 17.99, 
14.15, 10.95, -4.40, -4.80; HRMS-(ESI+) for C13H28O3SiNa [M + Na]+ calculated 283.1705 
Da, found 283.1711 Da. 
(S)-4-benzyl-3-((2S,3R,4S,6S)-3-hydroxy-2,4,6-trimethyltetracosanoyl)oxazolidin-2-one  
(5.15): To a stirred solution of alcohol 5.9 (160 mg, 0.45 
mmol) in DCM (3 mL) was added Dess-Martin periodinane 
(1.3 eq, 1.3 mL, 15% solution in DCM). The reaction was 
stirred until complete conversion was obtained (1–2 h), and an aq. saturated solution of 
Na2S2O3 (5 mL) was added. Stirring was continued until both layers were clear and then 
the layers were separated. The aq. layer was extracted with Et2O (2 x 5 mL) and the 
combined organic fractions were dried over MgSO4, filtered and concentrated. The crude 
aldehyde 5.14 was used in the next step without further purification.  
To oxazolidinone 5.10[8] (120 mg, 0.51 mmol) in DCM (1.5 mL) at 0 ºC, was slowly added 
n-Bu2BOTf (1.15 eq, 591 μL, 1 M solution in DCM, fresh bottle) over 5 min, followed by 
addition of Et3N (1.3 eq, 94 μL). The reaction mixture was cooled to –78 ºC, and aldehyde 
5.14 (183 mg, 0.52 mmol, dissolved in a minimum amount of DCM), was slowly added. 
After stirring for 20 min at –78ºC, the reaction was allowed to gradually warm to 0 ºC and 
stirred at this temperature for an additional hour. The reaction was subsequently quenched 
with  KH2PO4 buffer (1 mL, 0.1 M, pH 7) and MeOH (2 mL). MeOH/H2O2 (2 mL, 2:1, 50%) 
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was added and the resulting solution was stirred vigorously for 1 h. The mixture was 
diluted with H2O (3 mL) and extracted with Et2O (3 x 10 mL). The combined organic layers 
were successively washed with an aq. saturated solution of NaHCO3 and brine. The 
organic phase was dried over MgSO4, filtered and concentrated. The crude was purified 
using column chromatography (pentane/EtOAc 10:1) to afford 5.15 as a white solid (211 
mg, 70% over two steps). Although a slight chemical shift in the 1H- and 13C-NMR spectra 
was observed compared to reported, this is most probably due to a concentration 
difference. Mass analysis confirmed the formation of the desired product.[8] HRMS-(ESI+) 
for C43H77NO4Si [M + H]+ calculated 586.4830 Da, found 586.4817 Da. 
(S)-4-benzyl-3-((2S,3R,4S,6S)-3-((tert-butyldimethylsilyl)oxy)-2,4,6-
trimethyltetracosanoyl)oxazolidin-2-one (5.16): To a solution of 5.15 in DCM (1.7 mL, 
substrate concentration = 0.1 M) at 0 ºC, was added 2,6-
lutidine (1.4 eq, 28 μL), followed by TBSOTf (1.1 eq, 
43 μL). The reaction was stirred at this temperature for 1 h 
and an additional 14 h at rt, prior to quenching with KH2PO4 buffer (1 mL, 0.1 M, pH 7). The 
aqueous layer was extracted with DCM (3 x 5 mL) and the combined organic layers were 
dried over MgSO4, filtered and evaporated. 5.16 (95 mg, 79%) was isolated after column 
chromatography (pentane/EtOAc 30:1) as a colorless oil.  
1H NMR (400 MHz, CDCl3) δ 7.38 – 7.15 (m, 5H), 4.69 – 4.57 (m, 1H), 4.24 – 4.11 (m, 2H), 
4.04 – 3.89 (m, 2H), 3.26 (dd, J = 13.3, 3.2 Hz, 1H), 2.77 (dd, J = 13.3, 9.6 Hz, 1H), 1.67 – 
1.52 (m, 1H), 1.52 – 1.36 (m, 2H), 1.36 – 1.14 (m, 36H), 0.99 (ddd, J = 14.3, 8.1, 6.4 Hz, 
2H), 0.93 (s, 9H), 0.86 (dt, J = 16.2, 6.8 Hz, 9H), 0.09 (s, 3H), 0.08 (s, 3H); 13C NMR (101 
MHz, CDCl3) δ 176.20, 152.80, 135.25, 129.43, 128.90, 127.32, 75.97, 65.86, 55.47, 
41.72, 41.65, 37.66, 36.40, 35.78, 31.92, 30.09, 29.74, 29.70, 29.65, 29.35, 26.84, 26.18, 
22.68, 20.18, 18.47, 15.04, 14.99, 14.11, –3.59, –3.89; HRMS-(ESI+) for C43H77NO4Si [M + 
Na]+ calculated 722.5520 Da, found 722.5506 Da. 
(2S,3R,4S,6S)-3-((tert-butyldimethylsilyl)oxy)-2,4,6-trimethyltetracosanoic acid (5.17): To a 
solution of 5.16 (95 mg, 0.14 mmol) in THF/H2O (2.5 mL, 
4:1), was added H2O2 (4 eq, 33 μL, 50%) and LiOH (1.5 eq, 
4.9 mg) at 0 ºC. The mixture was allowed to slowly warm to rt 
and stirred for 18 h. The reaction was quenched by the addition of aq. saturated NaHSO3 
(2 mL) and acidified afterwards with aq. citric acid (20 w/w%) to pH 3–4. The mixture was 
extracted with EtOAc (3 x 5 mL) and the combined organic layers were dried over Na2SO4, 





(pentane/EtOAc/AcOH 9:1:0.05) to afford carboxylic acid 5.17 (44 mg, 60%) as a white 
solid.  
1H NMR (400 MHz, CDCl3) δ 3.86 – 3.82 (m, 1H), 2.70 – 2.56 (m, 1H), 1.73 – 1.63 (m, 1H), 
1.50 – 1.41 (m, 1H), 1.35 – 1.20 (m, 36H), 1.17 (dd, J = 7.0, 1.2, 3H), 0.91 (d, J = 1.5, 9H), 
0.89 – 0.83 (m, 9H), 0.08 (d, J = 1.2, 3H), 0.06 (d, J = 1.2, 3H); 13C NMR (101 MHz, CDCl3) 
δ 181.06, 76.75, 43.46, 41.75, 36.25, 34.83, 31.94, 30.32, 30.11, 30.05, 29.72, 29.68, 
29.38, 26.85, 26.07, 22.70, 20.27, 18.37, 15.13, 14.12, 12.85, –3.98, –4.09; HRMS-(ESI+) 
for C33H69O3Si [M + H]+ calculated 541.5016 Da, found 541.5011 Da. 
Compound 5.4: Anhydrous trehalose (5.3, 2.09 g, 6.1 mmol) was dissolved in anhydrous 
DMF (30 mL, substrate concentration = 0.2 M) 
and stirred over freshly activated 4 Å molecular 
sieves. 10-Camphorsulfonic acid (0.05 eq, 71 mg, 
0.31 mmol) and 1,1-dimethoxycyclohexane (8.1 
eq, 7.51 mL, 49 mmol) were added and the 
mixture was placed under reduced pressure (200 
mbar, rotary evaporator) and heated at 60 ºC for 
4 h. Afterwards, the solvent was removed in 
vacuo and the crude white solid was purified using automated column chromatography 
(pentane/EtOAc 1:1 to pure EtOAc in 15 minutes). Although the major product proved to be 
the 4,6- and 4',6'-disubstituted trehalose, the trisubstituted 5.4 (1.21 g, 34%) was also 
isolated as a white solid. Analytical data were in accordance with those reported.[11] 
Compound 5.18: To compound 5.4 (200 mg, 0.34 mmol) in DCM (14 mL) containing 4 Å 
molecular sieves, was added palmitic acid (88 
mg, 0.34 mmol) and DMAP (44 mg, 0.36 mmol). 
The solution was cooled to 0 ºC, and DCC (85 
mg, 0.41 mmol) was added. After stirring for 15 
min, the solution was allowed to warm to rt. After 
an additional 4 h, the white precipitate was filtered 
off and rinsed with DCM (3x). The filtrate was 
concentrated and the resulting off-white solid was 
purified using column chromatography (pentane/EtOAc 9:1) to afford 5.18 as a white solid 
(175 mg, 62%).  
1H NMR (400 MHz, CDCl3) δ 5.33 (d, J = 3.0, 1H), 5.28 (d, J = 3.7, 1H), 4.81 (dd, J = 9.7, 
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3.7, 1H), 4.11 (t, J = 9.4, 1H), 4.01 (td, J = 9.5, 2.3, 1H), 3.97 – 3.92 (m, 2H), 3.84 (dd, J = 
10.4, 5.2, 1H), 3.81 – 3.69 (m, 3H), 3.64 – 3.55 (m, 2H), 3.49 (dd, J = 9.1, 3.0, 1H), 2.46 – 
2.34 (m, 2H), 2.20 – 2.10 (m, 1H), 2.00 – 1.85 (m, 2H), 1.83 – 1.72 (m, 2H), 1.72 – 1.38 (m, 
28H), 1.38 – 1.19 (m, 24H), 0.87 (t, J = 6.9, 3H); 13C NMR (101 MHz, CDCl3) δ 173.37, 
112.36, 99.87, 99.78, 93.85, 93.36, 76.02, 73.30, 72.95, 72.93, 72.91, 69.14, 66.24, 63.68, 
61.42, 37.88, 37.84, 36.19, 35.97, 34.04, 31.89, 29.67, 29.66, 29.64, 29.63, 29.56, 29.50, 
29.33, 29.18, 29.12, 27.80, 27.77, 25.54, 24.99, 24.78, 23.78, 23.48, 22.78, 22.66, 22.50, 
22.47, 14.09; HRMS-(ESI+) for C46H76O12Na [M + Na]+ calculated 843.5235 Da, found 
843.5222 Da.  
Compound 5.19: To carboxylic acid 5.13 (10 mg, 0.038 mmol) in benzene (1.3 mL), was 
added Et3N (11.2 μL, 0.081 mmol) and 
2,4,6-trichlorobenzoyl chloride (6.3 μL, 
0.040 mmol). After stirring for 1 h, 5.18 (31.5 
mg, 0.038 mmol) and DMAP (4.9 mg, 0.040 
mmol) were added. The reaction was stirred 
for 20 h after which it was quenched by the 
addition of sat. aq. NaHCO3 (2 mL). The 
product was extracted with EtOAc (3 x 5 
mL) and the combined organic layers were dried over MgSO4. After filtration, the solvent 
was evaporated and the product purified using column chromatography (pentane/EtOAc 
20:1) to afford 5.19 (39 mg, 96%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 5.41 (t, J = 9.8, 1H), 5.35 (d, J = 2.7, 1H), 5.33 (d, J = 3.7, 
1H), 4.90 (dd, J = 10.0, 3.7, 1H), 4.18 (t, J = 9.4, 1H), 4.05 (td, J = 10.1, 5.2, 1H), 3.95 (t, 
J = 9.3, 1H), 3.90 – 3.81 (m, 2H), 3.80 – 3.65 (m, 4H), 3.58 – 3.47 (m, 2H), 2.59 – 2.50 (m, 
1H), 2.43 – 2.25 (m, 2H), 2.18 – 2.08 (m, 2H), 1.90 – 1.83 (m, 1H), 1.82 – 1.18 (m, 57H), 
1.15 (d, J = 7.0, 3H), 0.94 – 0.82 (m, 15H), 0.06 (s, 6H); 13C NMR (101 MHz, CDCl3) 
δ 173.75, 173.01, 112.54, 99.74, 99.61, 93.71, 93.17, 75.94, 73.16, 72.84, 72.81, 71.06, 
68.72, 66.31, 63.88, 61.44, 61.32, 45.42, 41.93, 37.79, 37.67, 37.39, 36.20, 35.84, 33.85, 
31.87, 29.65, 29.64, 29.62, 29.61, 29.52, 29.47, 29.31, 29.14, 29.13, 27.71, 27.54, 26.96, 
25.83, 25.64, 25.51, 25.48, 25.41, 24.98, 24.94, 24.53, 23.80, 23.46, 22.64, 22.60, 22.53, 
22.44, 22.30, 18.08, 16.86, 14.90, 14.41, 14.39, 14.07, –4.35, –4.49; HRMS-(ESI+) for 






Compound 5.20: To 5.19 (30 mg, 0.028 mmol) was added aq. HCl/THF (2 mL, 1:1, 10%). 
The reaction was stirred for 48 h, after which it 
was quenched by the addition of solid NaHCO3 
(100 mg). Water (4 mL) and DCM (5 mL) were 
added and the layers were separated. The aq. 
layer was extracted with DCM/2-propanol (4:1, 
3x). The combined organic layers were dried over MgSO4, filtered and all volatiles were 
evaporated. The crude product was purified using column chromatography 
(DCM/MeOH/acetone 8:1:1) to afford 5.20 (4.1 mg, 20%) as a white solid.  
1H NMR (400 MHz, CDCl3/CD3OD 4:1) δ 5.37 (t, J = 9.7, 1H), 5.20 (d, J = 3.0, 1H), 5.02 (d, 
J = 3.5, 1H), 4.84 (dd, J = 10.1, 3.5, 1H), 3.75 – 3.69 (m, 1H), 3.67 – 3.61 (m, 3H), 3.57 – 
3.42 (m, 3H), 3.36 (t, J = 9.6, 1H), 2.48 – 2.40 (m, 1H), 2.22 (t, J = 7.3, 2H), 1.51 – 1.43 (m, 
3H), 1.43 – 1.35 (m, 2H), 1.26 – 1.12 (m, 33H), 1.08 (d, J = 7.1, 4H), 0.86 (t, J = 6.8, 3H), 
0.80 (t, J = 6.9, 3H); HRMS-(ESI+) for C35H64O14Na [M + Na]+ calculated 731.4194 Da, 
found 731.4188 Da. 
Compound 5.21: To carboxylic acid 5.17 (22 mg, 0.041 mmol) in benzene (1.3 mL), was 
added Et3N (12 μL, 0.085 mmol) 
and 2,4,6-trichlorobenzoyl chloride 
(6.7 μL, 0.043 mmol). After stirring 
for 1 h, 5.18 (33.4 mg, 0.041 
mmol) and DMAP (5.5 mg, 0.045 
mmol) were added. The reaction 
was stirred for 20 h after which it 
was quenched by the addition of 
sat. aq. NaHCO3 (2 mL). The product was extracted with EtOAc (3 x 5 mL) and the 
combined organic layers were dried over MgSO4. After filtration the solvent was 
evaporated and the product purified using column chromatography (pentane/EtOAc 20:1) 
to afford 5.21 (36 mg, 65%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 5.39 (t, J = 9.8, 1H), 5.35 (d, J = 3.0, 1H), 5.33 (d, J = 3.8, 
1H), 4.92 (dd, J = 10.0, 3.8, 1H), 4.17 (t, J = 9.4, 1H), 4.05 (td, J = 10.1, 5.2, 1H), 3.95 (t, 
J = 9.4, 1H), 3.89 – 3.83 (m, 2H), 3.81 – 3.64 (m, 4H), 3.54 (dd, J = 9.6, 4.9, 1H), 3.50 (dd, 
J = 9.2, 3.0, 1H), 2.61 – 2.53 (m, 1H), 2.40 – 2.23 (m, 2H), 2.19 – 2.06 (m, 2H), 1.91 – 1.82 
(m, 1H), 1.82 – 1.36 (m, 31H), 1.36 – 1.20 (m, 60H), 1.17 (d, J = 7.1, 3H), 0.94 – 0.84 (m, 
18H), 0.80 (d, J = 6.9, 3H), 0.07 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 174.68, 173.01, 
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112.61, 99.79, 99.63, 93.79, 93.23, 76.01, 75.13, 73.24, 72.93, 71.38, 71.01, 68.82, 66.39, 
63.86, 61.44, 61.42, 61.39, 43.47, 40.90, 37.87, 37.74, 36.97, 36.26, 35.89, 35.55, 33.84, 
31.92, 30.09, 30.03, 29.76, 29.75, 29.71, 29.71, 29.67, 29.66, 29.60, 29.56, 29.37, 29.36, 
29.23, 29.21, 27.79, 27.59, 26.96, 26.16, 25.93, 25.57, 25.41, 25.04, 24.55, 23.86, 23.52, 
22.69, 22.67, 22.57, 22.49, 22.42, 19.94, 18.44, 15.76, 15.24, 14.11, -3.83, -3.84; HRMS-




trimethyltetracosanoate (5.22): To 
compound 5.21 (30 mg, 0.028 mmol) 
was added aq. HCl/THF (2 mL, 1:1, 
10%). The reaction was stirred for 48 
h, and subsequently quenched by the 
addition of solid NaHCO3 (100 mg). Water (4 mL) and DCM (5 mL) were added, and the 
layers were separated. The aq. layer was extracted with DCM/2-propanol (4:1, 3x). The 
combined organic layers were dried over MgSO4, filtered and all volatiles were evaporated. 
The crude product was purified using column chromatography (DCM/MeOH 15:1). 1H-NMR 
spectroscopy revealed that the TBS ether was untouched. To the remaining material was 
added CH3CN (0.7 mL) and 3 drops of HF (40% in H2O). After stirring for 20 h, the reaction 
was quenched by the addition of saturated aq. NaHCO3 (2 mL). The layers were 
separated, and the aqueous layer was extracted with DCM (2 x 5 mL). The combined 
organic layers were dried over MgSO4, filtered, and all volatiles were evaporated. TLC 
analysis indicated no conversion of the starting material, and the title compound was 
isolated.  
1H NMR (400 MHz, CDCl3) δ 5.39 (t, J = 9.8, 1H), 5.35 (d, J = 3.0, 1H), 5.33 (d, J = 3.8, 
1H), 4.92 (dd, J = 10.0, 3.8, 1H), 4.17 (t, J = 9.4, 1H), 4.05 (td, J = 10.1, 5.2, 1H), 3.95 (t, 
J = 9.4, 1H), 3.89 – 3.83 (m, 2H), 3.81 – 3.64 (m, 4H), 3.54 (dd, J = 9.6, 4.9, 1H), 3.50 (dd, 
J = 9.2, 3.0, 1H), 2.61 – 2.53 (m, 1H), 2.40 – 2.23 (m, 2H), 2.19 – 2.06 (m, 2H), 1.91 – 1.82 
(m, 1H), 1.82 – 1.36 (m, 31H), 1.36 – 1.20 (m, 60H), 1.17 (d, J = 7.1, 3H), 0.94 – 0.84 (m, 
18H), 0.80 (d, J = 6.9, 3H), 0.07 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 174.68, 173.01, 
112.61, 99.79, 99.63, 93.79, 93.23, 76.01, 75.13, 73.24, 72.93, 71.38, 71.01, 68.82, 66.39, 
63.86, 61.44, 61.42, 61.39, 43.47, 40.90, 37.87, 37.74, 36.97, 36.26, 35.89, 35.55, 33.84, 





29.23, 29.21, 27.79, 27.59, 26.96, 26.16, 25.93, 25.57, 25.41, 25.04, 24.55, 23.86, 23.52, 
22.69, 22.67, 22.57, 22.49, 22.42, 19.94, 18.44, 15.76, 15.24, 14.11. 
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